9.45

0.53% 0.05

Pre-market: 9.50 0.05 +0.53%

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is traded at $9.45, with a volume of 1.95M. It is up +0.53% in the last 24 hours and down -12.01% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Previous Close:

$9.40

Open:

$9.55

24h Volume:

1.95M

Relative Volume:

1.38

Market Cap:

$1.00B

Revenue:

Net Income/Loss:

$-258.08M

P/E Ratio:

-3.4364

EPS:

-2.75

Net Cash Flow:

$-202.32M

1W Performance:

-9.74%

1M Performance:

-12.01%

6M Performance:

-49.87%

1Y Performance:

-67.75%

1-Day Range:

$8.94

$9.73

1-Week Range:

$8.94

$10.62

52-Week Range:

$8.94

$31.24

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

646-440-9100

Address

350 FIFTH AVENUE, NEW YORK, NY

Employee

268

Twitter

@rocketpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

RCKT's Discussions on Twitter

Compare RCKT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCKT Rocket Pharmaceuticals Inc	9.45	1.00B	0	-258.08M	-202.32M	-2.75
VRTX Vertex Pharmaceuticals Inc	479.79	123.21B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	246.75	31.94B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.00B	3.32B	-860.46M	-1.04B	-8.32

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	Wedbush	Outperform
Dec-18-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

02:29 AM

What is Leerink Partnrs’ Estimate for RCKT Q2 Earnings? - Defense World

02:29 AM

01:50 AM

Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $54.00 - Defense World

01:50 AM

Needham & Company LLC Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $42.00 - Defense World

01:50 AM

Mar 02, 2025

Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs - MSN

Mar 02, 2025

When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit? - Yahoo Finance Australia

Mar 02, 2025

Mar 01, 2025

Decoding Rocket Pharmaceuticals Inc (RCKT): A Strategic SWOT Ins - GuruFocus.com

Mar 01, 2025

Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus - MSN

Mar 01, 2025

Feb 28, 2025

Rocket Pharmaceuticals Advances Gene Therapy Pipeline - TipRanks

Feb 28, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat

Feb 28, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month LowHere's What Happened - MarketBeat

Feb 28, 2025

Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target - TipRanks

Feb 28, 2025

Rocket Pharmaceuticals Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Feb 28, 2025

Rocket Pharmaceuticals Rings the Opening Bell - Nasdaq

Feb 28, 2025

Cantor Fitzgerald cuts Rocket Pharmaceuticals target to $50 By Investing.com - Investing.com Canada

Feb 28, 2025

Rocket Pharmaceuticals price target lowered to $54 from $62 at Chardan - TipRanks

Feb 28, 2025

Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 28, 2025

Feb 27, 2025

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - BioSpace

Feb 27, 2025

Rocket Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025

Rocket Pharmaceuticals: Q4 Earnings Snapshot - San Francisco Chronicle

Feb 27, 2025

Rocket Pharmaceuticals: Q4 Earnings Snapshot -February 27, 2025 at 04:15 pm EST - Marketscreener.com

Feb 27, 2025

ROCKET PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Feb 27, 2025

Gene Therapy Pioneer Rocket Pharmaceuticals Secures Funding Through 2026 Despite Wider Losses - StockTitan

Feb 27, 2025

Feb 26, 2025